Grafa News and Videos — Page 599

Cogent Biosciences (NASDAQ:COGT) unveiled highly supportive preclinical findings for its novel small molecule therapeutic candidate, CGT1145, at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden.

UniFirst (NYSE:UNF) shareholders voted decisively to approve the company’s pending acquisition by Cintas (NASDAQ:CTAS) during a special meeting.

Cogent Biosciences (NASDAQ:COGT) announced detailed clinical results from its registration-directed APEX trial evaluating its investigational precision therapy, bezuclastinib, in patients with advanced systemic mastocytosis (AdvSM).

Independent Bank (NASDAQ:IBCP) secured key regulatory approvals required to complete its previously announced acquisition of HCB Financial, the parent company of Highpoint Community Bank.

Jazz Pharmaceuticals (NASDAQ:JAZZ) announced top-line results from the Phase 3 LAGOON clinical trial evaluating Zepzelca (lurbinectedin) in patients with relapsed, second-line metastatic small cell lung cancer (SCLC).

Baidu (NASDAQ:BIDU) announced that AmiGo, an on-demand autonomous mobility service developed through its Apollo Go intelligent driving division in partnership with Swiss Post's PostBus, has secured a special operating permit from Switzerland’s Federal Roads Office (FEDRO) for highly automated (Level 4) operations.

SharonAI Holdings (NASDAQ:SHAZ) announced a major six-year strategic compute collaboration with NVIDIA (NASDAQ:NVDA) to massively scale sovereign artificial intelligence infrastructure across Australia.

Stellar’s cross-border payment network continues to gain attention as its anchor system links blockchain settlement with real-world remittance corridors across several major markets.

MBX Biosciences (NASDAQ:MBX) announced detailed results from its 12-week Avail Phase 2 clinical trial and new one-year data from an ongoing open-label extension study evaluating its investigational endocrine therapy, canvuparatide.

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported new clinical trial data and supportive real-world evidence evaluating its hereditary angioedema (HAE) portfolio at the European Academy of Allergy and Clinical Immunology (EAACI) 2026 Annual Meeting in Istanbul, Turkey.